IMIDomics is a biotechnology company focused on Patient-Centric drug discovery for immune-mediated inflammatory diseases (IMIDs). Our goal is to discover new and impactful IMID drugs by focusing on carefully selected patients, and stratifying populations to identify those most likely to respond. IMIDomics is powered by a unique Clinical Discovery EngineTM, which integrates and analyzes proprietary clinical, epidemiological and patient-derived biomolecular datasets, generated in partnership with the Vall d’Hebron Institute of Research, to establish a deeper understanding of IMID diseases. By doing so, IMIDomics has identified previously unrecognized targets, six of which have been selected for development. By relying on access to well-defined patients and their clinically relevant samples, IMIDomics enhances the probability of successful IMID drug discovery and development for those in need.
Company Details
- Employees
- 30
- Address
- 1000 4th St, San Rafael,california 94901,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.imidomics.com/
- Keywords
- Oryzon Genomics SA.
- HQ
- San Rafael, California
Imidomics Inc. Questions
Imidomics Inc.'s website is http://www.imidomics.com/
Imidomics Inc.'s LinkedIn profile is https://www.linkedin.com/company/imidomics-inc
Imidomics Inc. has
30 employees.
View email and phone details for 30
employees at Imidomics Inc..
Imidomics Inc.'s industry is
Biotechnology Research
Imidomics Inc.'s top competitors are
Parc Científic De Barcelona,
Evotec,
Oryzon Genomics Sa,
Angelini Ventures,
Formation Bio,
Endolipid Therapeutics,
Ona Therapeutics,
Doctis Project,
Splicebio,
Abac Therapeutics.
Imidomics Inc.'s categories are Biotechnology Research
